Elliot Ehrich

5.3k total citations
49 papers, 4.3k citations indexed

About

Elliot Ehrich is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Elliot Ehrich has authored 49 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pharmacology, 10 papers in Cellular and Molecular Neuroscience and 9 papers in Psychiatry and Mental health. Recurrent topics in Elliot Ehrich's work include Inflammatory mediators and NSAID effects (15 papers), Schizophrenia research and treatment (8 papers) and Treatment of Major Depression (8 papers). Elliot Ehrich is often cited by papers focused on Inflammatory mediators and NSAID effects (15 papers), Schizophrenia research and treatment (8 papers) and Treatment of Major Depression (8 papers). Elliot Ehrich collaborates with scholars based in United States, Canada and Ireland. Elliot Ehrich's co-authors include Bernard L. Silverman, James A. Bolognese, Mark M. Davis, Beth C. Seidenberg, Jeffrey L. Jorgensen, Philip A. Reay, Ryan Z. Turncliff, David J. Watson, N. Bellamy and John W. Loewy and has published in prestigious journals such as Cell, JAMA and The Journal of Experimental Medicine.

In The Last Decade

Elliot Ehrich

48 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elliot Ehrich United States	31	1.8k	640	609	561	508	49	4.3k
Arlene R. Hughes United States	25	1.7k 0.9×	1.2k 1.9×	749 1.2×	377 0.7×	263 0.5×	48	7.6k
Pierluigi Navarra Italy	43	575 0.3×	932 1.5×	674 1.1×	445 0.8×	557 1.1×	246	6.6k
Andrew Fitton United Kingdom	34	597 0.3×	156 0.2×	407 0.7×	324 0.6×	518 1.0×	53	4.1k
Carmen Martínez Spain	44	585 0.3×	1.1k 1.7×	2.1k 3.5×	383 0.7×	827 1.6×	136	5.5k
Jun Tian China	40	345 0.2×	639 1.0×	580 1.0×	286 0.5×	368 0.7×	228	5.4k
Akiko Okamoto Japan	34	530 0.3×	627 1.0×	386 0.6×	84 0.1×	817 1.6×	156	4.3k
Luis Álvarez Spain	40	456 0.3×	254 0.4×	627 1.0×	545 1.0×	1.6k 3.2×	178	6.3k
Colin J.D. Ross Canada	50	398 0.2×	302 0.5×	588 1.0×	422 0.8×	993 2.0×	217	7.4k
Abdulmaged M. Traish United States	58	1.4k 0.8×	394 0.6×	237 0.4×	254 0.5×	476 0.9×	213	10.1k
Elliot F. Ellis United States	42	654 0.4×	358 0.6×	562 0.9×	800 1.4×	494 1.0×	130	5.8k

Countries citing papers authored by Elliot Ehrich

Since Specialization

Citations

This map shows the geographic impact of Elliot Ehrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliot Ehrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliot Ehrich more than expected).

Fields of papers citing papers by Elliot Ehrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elliot Ehrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliot Ehrich. The network helps show where Elliot Ehrich may publish in the future.

Co-authorship network of co-authors of Elliot Ehrich

This figure shows the co-authorship network connecting the top 25 collaborators of Elliot Ehrich. A scholar is included among the top collaborators of Elliot Ehrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliot Ehrich. Elliot Ehrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial. The Journal of Clinical Pharmacology. 59(2). 206–217. 8 indexed citations

Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Samidorphan: A Phase I, Oxycodone‐, Pentazocine‐, Naltrexone‐, and Placebo‐Controlled Study. The Journal of Clinical Pharmacology. 59(2). 218–228. 11 indexed citations

Potkin, Steven G., Robert Risinger, Yangchun Du, et al.. (2017). Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophrenia Research. 190. 115–120. 12 indexed citations

Nasrallah, Henry A., John W. Newcomer, Robert Risinger, et al.. (2016). Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. The Journal of Clinical Psychiatry. 77(11). 1519–1525. 29 indexed citations

Shram, Megan J., Bernard L. Silverman, Elliot Ehrich, Edward M. Sellers, & Ryan Z. Turncliff. (2015). Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist. Journal of Clinical Psychopharmacology. 35(3). 242–249. 49 indexed citations

Meltzer, Herbert Y., Robert Risinger, Henry A. Nasrallah, et al.. (2015). A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia. The Journal of Clinical Psychiatry. 76(8). 1085–1090. 100 indexed citations

Citrome, Leslie, Yangchun Du, Robert Risinger, et al.. (2015). Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology. 31(2). 69–75. 17 indexed citations

McElroy, Susan L., Anna I. Guerdjikova, Thomas J. Blom, et al.. (2013). A placebo‐controlled pilot study of the novel opioid receptor antagonist ALKS‐33 in binge eating disorder. International Journal of Eating Disorders. 46(3). 239–245. 36 indexed citations

Dunbar, Joi, Ryan Z. Turncliff, Qunming Dong, et al.. (2006). Single‐ and Multiple‐Dose Pharmacokinetics of Long‐acting Injectable Naltrexone. Alcoholism Clinical and Experimental Research. 30(3). 480–490. 94 indexed citations

10.

Garbutt, James C., Henry R. Kranzler, Stephanie S. O’Malley, et al.. (2005). Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence. JAMA. 293(13). 1617–1617. 461 indexed citations

11.

Turncliff, Ryan Z., Joi Dunbar, Qunming Dong, et al.. (2005). Pharmacokinetics of Long‐Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 45(11). 1259–1267. 24 indexed citations

12.

Johnson, Bankole A., Nassima Ait‐Daoud, Henri‐Jean Aubin, et al.. (2004). A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol Dependence. Alcoholism Clinical and Experimental Research. 28(9). 1356–1361. 62 indexed citations

13.

Bolognese, James A., Thomas J. Schnitzer, & Elliot Ehrich. (2003). Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthritis and Cartilage. 11(7). 499–507. 113 indexed citations

14.

Cannon, Grant W., et al.. (2000). Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis & Rheumatism. 43(5). 978–978. 225 indexed citations

15.

Brooks, Peter, Paul Emery, Jilly F. Evans, et al.. (1999). Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Lara D. Veeken. 38(8). 779–788. 171 indexed citations

16.

Brideau, Christine, Stacia Kargman, Aimée Dallob, et al.. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflammation Research. 45(2). 68–74. 241 indexed citations

17.

Schild, Hansjörg, Nasim Mavaddat, Elliot Ehrich, et al.. (1994). The nature of major histocompatibility complex recognition by γδ T cells. Cell. 76(1). 29–37. 344 indexed citations

18.

Ehrich, Elliot, Brigitte Devaux, Edwin P. Rock, et al.. (1993). T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen.. The Journal of Experimental Medicine. 178(2). 713–722. 85 indexed citations

19.

Jorgensen, Jeffrey L., Philip A. Reay, Elliot Ehrich, & Mark M. Davis. (1992). Molecular Components of T-Cell Recognition. Annual Review of Immunology. 10(1). 835–873. 259 indexed citations

20.

Ehrich, Elliot, Alister Craig, Annemarie Poustka, Anna‐Maria Frischauf, & Hans Lehrach. (1987). A family of cosmid vectors with the multi-copy R6K replication origin. Gene. 57(2-3). 229–237. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact